Biogen Uses its Own Superspreader Event to Aid COVID-19 Research | The Scientist Magazine®
Biogen - Биоген - Photos | Facebook
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity
Stocks making the biggest moves midday: Apple, Netflix, Biogen, Canopy Growth and more
Biogen - Home | Facebook
What clinical trials of the future might look like | Biogen
Biogen's new Alzheimer's drug slows cognitive decline: study - Boston Business Journal
UPDATED: Biogen insists Eisai relationship 'solid' as questions remain over lecanemab commercialization | Fierce Biotech
More Layoffs Hit Biogen as Drugmaker Cuts Multiple Sclerosis Team – NBC Boston
Biogen and Alcyone Therapeutics partner up for novel device for neurological ASO therapies
Biogen Alzheimer's Drug Coverage Threatens Minorities' Access
Personal Care Wipes - Hangzhou Biogen Hygiene Co., Ltd. - page 1.
Biogen is ready to roll on lecanemab production, CFO says
Biogen begins cutting jobs following disastrous debut of its Alzheimer's drug - The Boston Globe
Biogen teams up with Ginkgo Bioworks in gene therapy manufacturing pact - MedCity News
Biogen gears up Swiss manufacturing facility for potential aducanumab rollout | Fierce Pharma
Biogen's Qalsody Is a First for ALS Treatments - Bloomberg
Drug companies are making an accounting change after the SEC cracked down on Biogen - MarketWatch
Biogen Announces Positive Phase 1 Results, Plan to License and Develop Ionis Pharmaceuticals' Investigational Therapy BIIB067 for Familial ALS - Muscular Dystrophy Association
Biogen (BIIB) Loses Bid to Revive Patent on Tecfidera MS Drug - Bloomberg
Biogen and Novartis release Q1 earnings reports: Mixed results and hope for 2023
Biogen Seeks to Sublease Cambridge, Weston Properties - Banker & Tradesman
Biogen, at a Crossroads, Surges on Promising Alzheimer's Drug Assessment - WSJ
Biogen Plunges After Making Changes to Alzheimer's Drug Trial | BioSpace
